Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles
ObjectiveTransarterial chemoembolization (TACE) stands for an ideal therapy for patients with intermediate stage HCC. This study was carried out to observe the effect of microparticles-transarterial chemoembolization (microparticles-TACE, m-TACE) on the immune function of hepatocellular carcinoma (H...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.624789/full |
| _version_ | 1818875349061074944 |
|---|---|
| author | Zhizhong Ren Yuanxun Yue Yuewei Zhang Jiahong Dong Ying Liu Xiaowei Yang Xin Lin Xueqiang Zhao Zhanqi Wei Yu Zheng Tianxiao Wang |
| author_facet | Zhizhong Ren Yuanxun Yue Yuewei Zhang Jiahong Dong Ying Liu Xiaowei Yang Xin Lin Xueqiang Zhao Zhanqi Wei Yu Zheng Tianxiao Wang |
| author_sort | Zhizhong Ren |
| collection | DOAJ |
| description | ObjectiveTransarterial chemoembolization (TACE) stands for an ideal therapy for patients with intermediate stage HCC. This study was carried out to observe the effect of microparticles-transarterial chemoembolization (microparticles-TACE, m-TACE) on the immune function of hepatocellular carcinoma (HCC) patients by detecting the proportion of regulatory (Treg) cells in the peripheral blood of HCC patients before and after m-TACE, and to determine whether m-TACE has a positive regulatory effect on the immune function of HCC patients.Methods33 HCC patients treated with Gelatn Sponge Microparticles (GSMs-TACE) were enrolled. Flow cytometry was used to determine the proportion of Treg cells and CD4+/CD8+ T cells in peripheral blood of HCC patients 1 day before GSMs-TACE, 1 to 2 weeks and 3 to 5 weeks after GSMs-TACE, respectively.ResultsThe Tregs cell proportion of HCC patients was significantly higher than that of the healthy and cirrhosis controls and was associated with various clinical indicators of HCC patients. The Treg cell proportion in HCC patients with BCLC stage C was higher than that of stage B patients; The Treg cell proportion at 1 to 2 weeks postoperatively was 8.54 ± 1.27%, which was significantly lower than that before the GSMs-TACE. The Treg cell proportion at 3 to 5 weeks postoperatively was 7.59 ± 1.27%, which continued to decline. The ratio of CD4+/CD8+ T cells was 1.31 ± 0.56, 1.86 ± 0.73, 1.76 ± 0.58% (P<0.01) respectively.ConclusionThese results indicated that m-TACE could exert a positive regulatory effect on the anticancer immune function of HCC patients, which may be used in combination with immune adjuvant therapies to enhance the efficacy of HCC. |
| first_indexed | 2024-12-19T13:25:05Z |
| format | Article |
| id | doaj.art-1d13ec23357e42e5bd434120dc3fc037 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T13:25:05Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1d13ec23357e42e5bd434120dc3fc0372022-12-21T20:19:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-02-011210.3389/fimmu.2021.624789624789Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With MicroparticlesZhizhong Ren0Yuanxun Yue1Yuewei Zhang2Jiahong Dong3Ying Liu4Xiaowei Yang5Xin Lin6Xueqiang Zhao7Zhanqi Wei8Yu Zheng9Tianxiao Wang10Hepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaDepartment of Interventional and Pain, Beijing Luhe Hospital, Capital Medical University, Beijing, ChinaHepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaHepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaHepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaHepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaSchool for Medicine, Institute for Immunology, Tsinghua University, Beijing, ChinaSchool for Medicine, Institute for Immunology, Tsinghua University, Beijing, ChinaSchool for Medicine, Institute for Immunology, Tsinghua University, Beijing, ChinaSchool for Medicine, Institute for Immunology, Tsinghua University, Beijing, ChinaHepatobiliary Pancreatic Center Department, Beijing Tsinghua Changgung Hospital Affiliated to Tsinghua University, Beijing, ChinaObjectiveTransarterial chemoembolization (TACE) stands for an ideal therapy for patients with intermediate stage HCC. This study was carried out to observe the effect of microparticles-transarterial chemoembolization (microparticles-TACE, m-TACE) on the immune function of hepatocellular carcinoma (HCC) patients by detecting the proportion of regulatory (Treg) cells in the peripheral blood of HCC patients before and after m-TACE, and to determine whether m-TACE has a positive regulatory effect on the immune function of HCC patients.Methods33 HCC patients treated with Gelatn Sponge Microparticles (GSMs-TACE) were enrolled. Flow cytometry was used to determine the proportion of Treg cells and CD4+/CD8+ T cells in peripheral blood of HCC patients 1 day before GSMs-TACE, 1 to 2 weeks and 3 to 5 weeks after GSMs-TACE, respectively.ResultsThe Tregs cell proportion of HCC patients was significantly higher than that of the healthy and cirrhosis controls and was associated with various clinical indicators of HCC patients. The Treg cell proportion in HCC patients with BCLC stage C was higher than that of stage B patients; The Treg cell proportion at 1 to 2 weeks postoperatively was 8.54 ± 1.27%, which was significantly lower than that before the GSMs-TACE. The Treg cell proportion at 3 to 5 weeks postoperatively was 7.59 ± 1.27%, which continued to decline. The ratio of CD4+/CD8+ T cells was 1.31 ± 0.56, 1.86 ± 0.73, 1.76 ± 0.58% (P<0.01) respectively.ConclusionThese results indicated that m-TACE could exert a positive regulatory effect on the anticancer immune function of HCC patients, which may be used in combination with immune adjuvant therapies to enhance the efficacy of HCC.https://www.frontiersin.org/articles/10.3389/fimmu.2021.624789/fullhepatocellular carcinomaTreg cellsm-TACEtumor immunityflow cytometry |
| spellingShingle | Zhizhong Ren Yuanxun Yue Yuewei Zhang Jiahong Dong Ying Liu Xiaowei Yang Xin Lin Xueqiang Zhao Zhanqi Wei Yu Zheng Tianxiao Wang Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles Frontiers in Immunology hepatocellular carcinoma Treg cells m-TACE tumor immunity flow cytometry |
| title | Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles |
| title_full | Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles |
| title_fullStr | Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles |
| title_full_unstemmed | Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles |
| title_short | Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles |
| title_sort | changes in the peripheral blood treg cell proportion in hepatocellular carcinoma patients after transarterial chemoembolization with microparticles |
| topic | hepatocellular carcinoma Treg cells m-TACE tumor immunity flow cytometry |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.624789/full |
| work_keys_str_mv | AT zhizhongren changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT yuanxunyue changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT yueweizhang changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT jiahongdong changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT yingliu changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT xiaoweiyang changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT xinlin changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT xueqiangzhao changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT zhanqiwei changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT yuzheng changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles AT tianxiaowang changesintheperipheralbloodtregcellproportioninhepatocellularcarcinomapatientsaftertransarterialchemoembolizationwithmicroparticles |